Coherus Biosciences Inc CHRS

Coherus Biosciences Inc is an American biopharmaceutical company headquartered in the San Francisco Bay Area. Founded in 2007, it develops, manufactures, and distributes biologic therapies for the treatment of various diseases, with a primary focus on the treatment of inflammatory diseases and oncology. The company develops biosimilar treatments for commercialisation across the US and internationally.

The company’s products include Udenyca, an FDA-approved biosimilar administered following chemotherapy to lower the risk of infection, which is the most frequently prescribed pegfilgrastim prefilled syringe. Other products in the pipeline are aimed at those with various cancers including breast, lung, and skin, with biosimilars in the area on oncology, ophthalmology, and immunology all in the clinical trial phase.

Coherus has a focus on process science, analytical characterisation, protein production, and clinical-regulatory development, with the aim of delivering cost-effective medicines and facilitating significant savings to the US healthcare system. The company’s scientific advisory board is made up of scientific and clinical advisors who have made significant contributions in the field of immuno-oncology. Coherus Biosciences is listed on the NASDAQ under the stock ticker CHRS.

If you are interested in tracking the price movements of this company you can add CHRS stock to your eToro watchlist to receive real-time updates.